Prostate Cancer is a new Decision Resources study that evaluates dynamic market changes regarding this highly prevalent disease. Prostate cancer (CaP) has recently emerged as a disease worthy of aggressive drug therapy. Clinicians now recognize that, in its aggressive form, CaP can affect relatively young and otherwise healthy men, significantly shortening their life span. This realization is changing treatment patterns and will substantially increase sales of chemotherapy drugs and certain hormonal therapies.
Vigorous growth in sales of chemotherapy agents is the most significant new trend we anticipate in the treatment of CaP. Recent positive results with chemotherapy agents are paving the way for a substantial increase in their use to treat CaP. Widespread use of chemotherapy will address one of the key unmet needs in CaP drug therapy: the treatment of patients with hormone-refractory, metastatic CaP (a subset of patients with stage IV CaP). We anticipate that clinicians will also use chemotherapy regimens for preventing the recurrence and progression of both advanced (stage III or IV) and aggressive forms of early-stage (I or II) CaP. We expect that by the midpoint of our 1999-2009 forecast period, clinicians will use chemotherapy agents in a substantially greater proportion of patients with metastatic CaP than was the case in 1999. We expect that by 2009, clinicians will use chemotherapy agents in 30% of the incident patient population diagnosed with locally advanced (clinical) stage III CaP. (In current clinical practice, chemotherapy has no role in treating locally advanced CaP, and a patient is likely to be treated by an oncologist only when he has developed hormone-refractory, metastatic disease.)
In the hormone therapy arena, LHRH analogues will face increasing competition from anti-androgens during our forecast period, because urologists believe that these latter drugs have a better side-effect profile. LHRH analogues (in 1999, the most widely used class of hormonal therapy) will lose their lead in market share to the anti-androgen class but maintain their current level of sales.
Prostate Cancer offers invaluable market intelligence for pharmaceutical companies developing drugs to treat this indication. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 201-369-3467
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., 781-296-2553, or